Development of vaccine delivery vehicles based on lactic acid bacteria

Molecular Biotechnology

Volumn 51, Issue 2, 2012, Pages 183-199

  Tarahomjoo, Shirin ^a,b  

^a RAZI VACCINE AND SERUM RESEARCH INSTITUTE   (Iran)

^b AMIRKABIR UNIVERSITY OF TECHNOLOGY   (Iran)

Author keywords

Antigen; Immunization route; Lactic acid bacteria; Live vaccine; Vaccine delivery

Indexed keywords

ANTIGEN DELIVERY SYSTEM; IMMUNE RESPONSE; LACTIC ACID BACTERIA; PATHOGENIC MICROORGANISMS; PATHOGENIC ORGANISMS; RECOMBINANT BACTERIA; RECOMBINANT BACTERIAL VECTOR; TETANUS TOXIN; VACCINE DELIVERY;

ANTIGENS; BACTERIA; LACTIC ACID;

VACCINES;

DRUG VEHICLE; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 12; LIVE VACCINE; MEROZOITE SURFACE PROTEIN 1; MITOMYCIN C; NEUTRALIZING ANTIBODY; PERTUSSIS TOXIN; TETANUS TOXIN; VIRUS ENVELOPE PROTEIN; VIRUS FUSION PROTEIN; VIRUS SPIKE PROTEIN; YERSINIA OUTER PROTEIN E;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; BACILLUS ANTHRACIS; BACTERIAL CELL; BACTERIAL VIRULENCE; BACTERIUM CARRIER; BORRELIA AFZELII; BORRELIA BURGDORFERI; CELL SURFACE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DENDRITIC CELL; DENGUE VIRUS; DNA IMMUNIZATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ERYSIPELOTHRIX RHUSIOPATHIAE; ESCHERICHIA COLI; GASTROINTESTINAL INFECTION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOCOMPETENCE; IMMUNOCOMPETENT CELL; IMMUNOCOMPROMISED PATIENT; INFECTIOUS DIARRHEA; INNATE IMMUNITY; LACTIC ACID BACTERIUM; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS HELVETICUS; LACTOBACILLUS PLANTARUM; LACTOBACILLUS REUTERI; LACTOCOCCUS LACTIS; LISTERIOSIS; MUCOSAL IMMUNITY; NATURAL KILLER CELL; NONHUMAN; NOSE MUCOSA; PHAGOCYTOSIS; PLASMODIUM; PORCINE PARVOVIRUS; RECEPTOR BINDING; REVIEW; SALMONELLA ENTERITIDIS; SALMONELLOSIS; SARS CORONAVIRUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; SURVIVAL TIME; T LYMPHOCYTE; TH1 CELL; TUMOR REGRESSION; TUMOR VOLUME; YERSINIA; YERSINIA PSEUDOTUBERCULOSIS; YERSINIOSIS;

ANIMALS; ANTIGENS; DRUG DELIVERY SYSTEMS; HUMANS; LACTOBACILLALES; MICE; VACCINES;

BACTERIA (MICROORGANISMS);

EID: 84860833653     PISSN: 10736085     EISSN: 15590305     Source Type: Journal    
DOI: 10.1007/s12033-011-9450-2     Document Type: Review

References (87)

1. Mielcarek, N., Alonso, S., & Locht, C. (2001). Nasal vaccination using live bacterial vectors. Advanced Drug Delivery Reviews, 51, 55-69. (Pubitemid 32763072)
2. Moore, R. J., Stewart, D. J., Lund, K., & Hodgson, L. M. (2001). Vaccination against ovine footrot using a live bacterial vector to deliver basic protease antigen. FEMS Microbiology Letters, 194, 193-196. (Pubitemid 32332783)
3. Giudice, E. L., & Campbell, J. D. (2006). Needle free vaccine delivery. Advanced Drug Delivery Reviews, 58, 68-89.
4. Formal, S. B., Baron, L. S., Kopecko, D. J., Washington, O., Powell, C., & Life, C. A. (1981). Construction of a potential bivalent vaccine strain: Introduction of Shigella sonnei form I antigen genes into the galE Salmonella typhi Ty21a typhoid vaccine strain. Infection and Immunity, 34, 746-750. (Pubitemid 12247171)
5. Curtiss, R. (2002). Bacterial infectious disease control by vaccine development. Journal of Clinical Investigation, 110, 1061-1066.
6. Konings, W., Kok, J., Kuipers, O. S., & Poolman, B. (2000). Lactic acid bacteria: The bugs of new millennium. Current Opinion in Microbiology, 3, 276-282. (Pubitemid 30368061)
7. Ross, R. P., Morgan, S., & Hill, C. (2002). Preservation and fermentation: Past, present and future. Int. Journal of Food Microbiology, 79, 3-16. (Pubitemid 36153033)
8. Schnurer, J., & Magnusson, J. (2005). Antifungal lactic acid bacteria as biopreservatives. Trends in Food Science & Technology, 16, 70-78. (Pubitemid 40984904)
9. Lee, J.-S., Poo, H., Han, D. P., Hong, S.-P., Kim, K., Cho, M. W., et al. (2006). Mucosal immunization with surface displayed severe acute respiratory syndrome coronovirus spike protein on Lactobacillus casei induces neutralization antibodies in mice. Journal of Virology, 80, 4079-4087.
10. Seegers, J. F. M. L. (2002). Lactobacilli as live vaccine delivery vectors: Progress and prospects. Trends in Biotechnology, 20, 508-515. (Pubitemid 35356405)
11. Wells, J. M., Robinson, K., Chamberlin, L. M., Schofield, K. M., & Le Page, R. W. F. (1996). Lactic acid bacteria as vaccine delivery vehicles. Anton van Leeuwenhoek, 70, 317-330. (Pubitemid 26355506)
12. Dale, J. B. (2008). Current status of group A streptococcal vaccine development. In A. Finn & A. J. Pollard (Eds.), Hot topics in infection and immunity in children IV (pp. 53-63). NY: Springer.
13. Mannam, P., Jones, K. F., & Geller, B. L. (2004). Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes. Infection and Immunity, 72, 3444-3450. (Pubitemid 38697770)
14. Dramsi, S., Caliot, E., Bonne, I., Guadagnini, S., Prevost, M. C., Kojadinavic, M., et al. (2006). Assembly and role of pili in group B. streptococci. Molecular Microbiology, 60, 1401-1413. (Pubitemid 43801433)
15. Buccato, S., Maione, D., Rinaudo, C. D., Volpini, G., Taddei, A. R., Rosini, R., et al. (2006). Use of Lactococcus lactis expressing pili from group B Streptococcus as a broad-coverage vaccine against streptococcal disease. The Journal of Infectious Diseases, 194, 331-340. (Pubitemid 44116975)
16. Bogaert, D., Hermans, D. W., Adrian, P. V., Rumke, H. C., & de Groot, R. (2004). Pneumococcal vaccines: An update on current strategies. Vaccine, 2, 2209-2220. (Pubitemid 38626060)
17. Campos, I. B., Darrieux, M., Ferreira, D. M., Miyaji, E. N., Silva, D. A., Areas, A. P. M., et al. (2008). Nasal immunization of mice with Lactobacillus casei expressing the pneumococcal surface protein A: Induction of antibodies, complement deposition and partial protection against Streptococcus pneumoniae challenge. Microbes and Infection, 10, 481-488.
18. Hannify, S. B., Carter, A. T., Hitchin, E., & Wells, J. M. (2007). Mucosal delivery of a pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection. The Journal of Infectious Diseases, 195, 185-193. (Pubitemid 46080050)
19. Oliviera, M. L. S., Areas, A. P. M., Campos, I. B., Monedro, V., Perez-Martinez, G., Miyaji, E. N., et al. (2006). Induction of systemic and mucosal immune response and decrease in Streptococcus pneumoniae colonization by nasal inoculation of mice with recombinant lactic acid bacteria expressing pneumococcal surface antigen A. Microbes and Infection, 8, 1016-1024.
20. Pouwels, P. H., Leer, R. J., Shaw, M., den Bak-Glashouwer, M.-J. H., Tielen, F. D., Smit, E., et al. (1998). Lactic acid bacteria as antigen delivery vehicles for oral immunization purposes. International Journal of Food Microbiology, 41, 155-167. (Pubitemid 28369429)
21. Wells, J. M., Robinson, K., Chamberlain, L. M., Schofield, K. M., & Le Page, R. W. F. (1996). Lactic acid bacteria as vaccine delivery vehicles. Anton van Leeuwenhoek, 70, 317-330. (Pubitemid 26355506)
22. Green, B. A., Zhang, Y., Masi, A. W., Barniak, V., Wheterell, M., Smith, R. P., et al. (2005). PppA, a surface exposed protein of Streptococcus pneumoniae, elicits cross-reactive antibodies that reduce colonization in a murine intranasal immunization and challenge model. Infection and Immunity, 73, 981-989. (Pubitemid 40165758)
23. Medina, M., Villena, J., Vintini, E., Hebert, E. M., Raya, R., & Alvarez, S. (2008). Nasal immunization with Lactococcus lactis expressing the pnemococcal protective protein A induces protective immunity in mice. Infection and Immunity, 76, 2696-2705.
24. Corthesy-Theulaz, I., Porta, N., Glauser, M., Sarage, E., Vaney, A. C., Haas, R., et al. (1995). Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacteri infection in mice. Gastroenterology, 109, 115-121.
25. Gu, Q., Song, D., & Zhu, M. (2009). Oral vaccination of mice against Helicobacter pylori with recombinant Lactococcus lactis expressing urease subunit B. FEMS Immunology and Medical Microbiology, 56, 197-203.
26. Corthesy, B., Boris, S., Isler, P., Grangette, C., & Mercenier, A. (2005). Oral immunization of mice with lactic acid bacteria producing Helicobacter pylori Urease B subunit partially protects against challenge with Helicobacter felis. The Journal of Infectious Diseases, 192, 1441-1449. (Pubitemid 41401159)
27. Walker, R. I., Steel, D., & Aguado, T. (2007). Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic E. coli (ETEC) disease. Vaccine, 25, 2545-2566. (Pubitemid 46400935)
28. Wu, C.-M., & Chung, T.-C. (2007). Mice protected by oral immunization with Lactobacillus reuteri secreting fusion proteins of Escherichia coli enterotoxin subunit protein. FEMS Immunology and Medical Microbiology, 50, 354-365. (Pubitemid 47041458)
29. Nagy, B., & Feket, P. Z. (2005). Enterotoxigenic Escherichia coli in veterinary medicine. International Journal of Medical Microbiology, 295, 443-454. (Pubitemid 41225455)
30. Wei, C.-H., Liu, J.-K., Hou, X.-L., Yu, L.-Y., Lee, J.-S., & Kim, C.-J. (2010). Immunogenicity and protective efficacy of orally or intranasally administered recombinant Lactobacillus casei expressing ETEC K99. Vaccine, 28, 4113-4118.
31. Chu, H., Kang, S., Ha, S., Cho, K., Park, S.-M., Han, K.-H., et al. (2005). Lactobacillus acidophilus expressing recombinant K99 adhesive fimbriae has an inhibitory effect on adhesion of enterotoxigenic Escherichia coli. Microbiology and Immunology, 49, 941-948. (Pubitemid 41687167)
32. Liu, J.-K., Hou, X.-L., Wei, C.-H., Yu, L.-Y., He, X.-J., Wang, G.-H., et al. (2009). Induction of immune responses in mice after oral immunization with recombinant Lactobacillus casei strains expressing enterotoxigenic Escherichia coli F41 fimbrial protein. Applied and Environmental Microbiology, 75, 4491-4497.
33. Hu, C. X., Xu, Z. R., Li, W. F., Dong, N., Lu, P., & Fu, L. L. (2009). Secretory expression of K88 (F4) fimbrial adhesin FaeG by recombinant Lactococcus lactis for oral vaccination and its protective immune response in mice. Biotechnology Letters, 31, 991-997.
34. Smeds, A., Hemmann, K., Jakava-Viljanen, M., Pelkinen, S., Imberechts, H., & Palva, A. (2001). Characterization of the adhesin of Escherichia coli F18 fimbriae. Infection and Immunity, 69, 7941-7945. (Pubitemid 33086631)
35. Lindholm, A., Smeds, A., & Palva, A. (2004). Receptor binding domain of Escherichia coli F18 fimbrial adhesin FedF can be both efficiently secreted and surface displayed in a functional form in Lactococcus lactis. Applied and Environmental Microbiology, 70, 2061-2071. (Pubitemid 38500504)
36. Toyota-Hantani, Y., Inoue, M., Ekawa, T., Ohta, H., Igimi, S., & Baba, E. (2008). Importance of the major FliC antigenic site of Salmonella enteritidis as a subunit vaccine antigen. Vaccine, 26, 4135-4137.
37. Ramos, H. C., Rumbo, M., & Sirad, J.-C. (2004). Bacterial flagellins: Mediators of pathogenicity and host immune responses in mucosa. Trends in Microbiology, 12, 509-517. (Pubitemid 39370733)
38. Kajikawa, A., Satoh, E., Leer, R. J., Yamamoto, S., & Igimi, S. (2007). Intragastic immunization with recombinant Lactobacillus casei expressing flagellar antigen confers antibody-independent protective immunity against Salmonella enterica serovar Enteritidis. Vaccine, 25, 3599-3605. (Pubitemid 46575090)
39. Vazquez-Boland, J. A., Kuhn, M., Berche, P., Chakraborty, T., Dominguez-Bernal, G., & Goebel, W. (2001). Listeria pathogenesis and virulence determinants. Clinical Microbiology Reviews, 14, 584-640.
40. Harty, J. T., & Pamer, E. G. (1995). CD8? T lymphocytes specific for the secreted p60 antigen protects against Listeria monocytogenes infection. Journal of Immunology, 154, 4642-4650.
41. Bahey-El-Din, M., Casey, P. G., Griffin, B. T., & Gahan, C. G. M. (2008). Lactococcus lactis-expressing listeriolysin O (LLO) provides protection and specific CD8? T cells against Listeria monocytogenes in the murine infection model. Vaccine, 26, 5304-5314.
42. Halling-Brown, M., Sansom, C. E., Avies, M., Titball, R. W., & Moss, D. S. (2008). Are bacterial vaccine antigens T-cell epitope depleted. Trends in Immunology, 29, 374-379.
43. Overheim, K. A., DePaolo, R. W., Debord, K. L., Morrin, E. M., Anderson, D. M., Green, N. M., et al. (2005). LcrV plaque vaccine with altered immunomodulatory properties. Infection and Immunity, 73, 5152-5159. (Pubitemid 41105674)
44. Daniel, C., Sebbane, F., Poiret, S., Goudercourt, D., Dewulf, J., Mullet, C., et al. (2009). Protection against Yersinia pseudotuberculosis infection conferred by a Lactococcus lactis mucosal delivery vector secreting LcrV. Vaccine, 27, 1141-1144.
45. Friedlander, A. M., & Little, S. F. (2009). Advances in the development of next- generation anthrax vaccines. Vaccine, 27, D28-D32.
46. Mohammadzadeh, M., Duong, T., Sandwick, S. J., Hoover, T., & Klaenhammer, T. R. (2009). Dendritic cell targeting of Bacillus anthracis protective antigen expressed by Lactobacillus acidophilus protects mice from lethal challenge. Proceedings of the National Academy of Science, 106, 4331-4336.
47. Coker, C., Poore, C. A., Li, X., & Mobely, H. L. (2000). Pathogenesis of Proteus mirabilis urinary tract infection. Microbes and Infection, 2, 1497-1509.
48. Scavone, P., Miyoshi, A., Rial, A., Chabalgoity, A., Langella, P., Azevedo, V., et al. (2007). Intranasal immunization with recombinant Lactococcus lactis displaying either anchored or secreted forms of Proteus mirabilis MrpA fimbrial protein confers specific immune response and induces a significant reduction of kidney bacterial colonization in mice. Microbes and Infection, 9, 821-828. (Pubitemid 46901040)
49. Witvliet, M. H., Burns, D. L., Brennan, M. J., Poolman, J. T., & Manclark, C. R. (1989). Binding of pertussis toxin to eukaryotic cells and glycoproteins. Infection and Immunity, 57, 3324-3330. (Pubitemid 19259857)
50. Lee, S. F., March, R. J., Halperin, S. A., Faulkner, G., & Gao, L. (1999). Surface expression of a protective recombinant pertussis toxin S1 subunit fragment in Streptococcus gordonii. Infection and Immunity, 67, 1511-1516. (Pubitemid 29108537)
51. Fikrig, E., Telford, S. R., Barthold, S. W., Kantor, F. S., Spielman, A., & Flavell, R. A. (1992). Elimination of Borrelia burgdorferi from vector ticks feeding on OspA- immunized mice. Proceedings of the National Academy of Science, 89, 5418-5421.
52. Rio, B. D., Dattwyler, R. J., Aroso, M., Neves, V., Meirelles, L., Seegers, J. F. M. L., et al. (2008). Oral immunization with recombinant Lactobacillus plantarum induces a protective immune response in mice with lyme disease. Clinical and Vaccine Immunology, 15, 1429-1435.
53. Shimoji, Y. (2000). Pathogenicity of Erysipelothrix rhusiopathiae: Virulence factors and protective immunity. Microbes and Infection, 9, 965-972. (Pubitemid 30483192)
54. Cheun, H. I., Kawamoto, K., Hiramatsu, M., Tamaoki, H., Shirahata, T., Igimi, S., et al. (2004). Protective immunity of SpaA-antigen producing Lactococcus lactis against Erysipelothrix rhusiopathiae infection. Journal of Applied Microbiology, 96, 1347-1353. (Pubitemid 38703616)
55. Wyatt, R., Sullivan, N., Thali, M., Repke, H., Ho, D., Robinson, J., et al. (1993). Functional and immunogenic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of major variable regions. Journal of Virology, 67, 4557-4565. (Pubitemid 23215934)
56. Xin, K.-Q., Hoshino, Y., Toda, Y., Igimi, S., Kojima, Y., Jounai, N., et al. (2003). Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env. Blood, 102, 223-228. (Pubitemid 36759658)
57. He, Y., Zhou, Y., Liu, S., Kou, Z., Li, W., Farzan, M., et al. (2004). Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralization antibodies: Implication for developing subunit vaccine. Biochemical and Biophysical Research Communications, 324, 773-781. (Pubitemid 39345582)
58. Krinbauer, R., Booy, F., Cheng, N., Lowy, D. R., & Schiller, J. T. (1992). Papillomavirus L1 major capsid protein self assembles into virus-like particles that are highly immunogenic. Proceedings of the National Academy of Science, 89, 12180-12184. (Pubitemid 23004809)
59. Kim, S. N., Jeong, H. S., Park, S. N., & Kim, H.-J. (2007). Purification and immunogenicity study of human papilomavirus type 16 L1 protein in Saccharomyces cerevisiae. Journal of Virological Methods, 139, 24-30. (Pubitemid 44872904)
60. Aires, K. A., Cianociarullo, A. M., Carneiro, S. M., Villa, L. L., Boccardo, E., Perez-Martinez, G., et al. (2006). Production of human papilomavirus type 16 L1 virus like particles by recombinant Lactobacillus casei cells. Applied and Environmental Microbiology, 72, 745-752.
61. Choo, C. K., Rorke, E. A., & Eckert, R. L. (1994). Differentiation- independent constitutive expression of the human papillomavirus type 16 E6 and E7 oncogenes in Caski cervical tumor cell line. Journal of General Virology, 75, 1139-1147. (Pubitemid 24143158)
62. Poo, H., Pyo, H.-M., Lee, T.-Y., Yoon, S.-W., Lee, J.-S., Kim, C.-J., et al. (2006). Oral administration of human papilomavirus type 16 E7 displayed on Lactobacillus casei induces E7-specific antitumor effects in C57/BL6 mice. International Journal of Cancer, 119, 1702-1709. (Pubitemid 44258780)
63. Bermudez-Humaran, L. G., Cortes-Perez, N. G., Lefever, F., Guimaraes, V., Rabot, S., Alcocer-Gonnzalez, J. M., et al. (2005). A novel mucosal vaccine based on live lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. Journal of Immunology, 175, 7297-7302. (Pubitemid 41713425)
64. Crill, W. D., Hughes, H. R., Delorey, M. J., & Chang, G.-J. J. (2009). Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. Plos One, 4, e4991.
65. Sim, A. C. N., Lin, W., Tan, G. K. X., Sim, M. S. T., Chow, V. T. K., & Alonso, S. (2008). Induction of neutralizing antibodies against dengue virus type 2 upon mucosal administration of a recombinant Lactococcus lactis strain expressing envelope domain III antigen. Vaccine, 26, 1145-1154.
66. Estes, M. K., & Cohen, J. (1989). Rotavirus gene structure and function. Microbiological Reviews, 53, 410-449. (Pubitemid 20006367)
67. Perez, C. A., Eichwald, C., Burrone, O., & de Mendoza, D. (2005). Rotavirus VP7 antigen produced by Lactococcus lactis induces neutralizing antibodies in mice. Journal of Applied Microbiology, 99, 1158-1164. (Pubitemid 41531306)
68. Li, Y.-J., Ma, G.-P., Li, G.-W., Qiao, X.-Y., Ge, J.-W., Tang, L.-J., et al. (2010). Oral vaccination with the porcine rotavirus VP4 outer capsid protein expressed by Lactococcus lactis induces specific antibody production. Journal of Biomedicine and Biotechnology, 2010, 1-9.
69. Qiao, X., Li, G., Wang, X., Li, X., Liu, M., & Li, Y. (2009). Recombinant porcine rotavirus VP4 and VP4-LTB expressed in Lactobacillus casei induced mucosal and systemic antibody responses in mice. BMC Microbiology, 9, 249.
70. Godet, M., Grosclaude, J., Delmas, B.,&Laude, H. (1994). Majorreceptor binding and neutralization determinants are located within the same domain of the transmissible gastroenteritis virus (coronavirus) spike protein. Journal of Virology, 68, 8008-8016. (Pubitemid 24362689)
71. Tang, L., & Li, Y. (2009). Oral immunization of mice with recombinant Lactococcus lactis expressing porcine transmissible gastroenteritis virus spike glycoprotein. Virus Genes, 39, 238-245.
72. Ho, P. S., Kwang, J., & Lee, Y. K. (2005). Intragstric administration of Lactobacillus casei expressing transmissible gastroenteritis coronavirus spike glycoprotein induced antibody production. Vaccine, 23, 1335-1342. (Pubitemid 40127325)
73. Hou, X.-L., Yu, L.-Y., Liu, J., & Wang, G.-H. (2007). Surfacedisplayed porcine epidemic diarrhea viral (PEDV) antigens on lactic acid bacteria. Vaccine, 26, 24-31. (Pubitemid 350213212)
74. Kamstrup, S., Langeveld, J., Botner, A., Nielson, J., Schaaper, W. M., Boshuizen, R. S., et al. (1998). Mapping the antigenic structure of porcine parvovirus at the level of peptides. Virus Research, 53, 163-173. (Pubitemid 28127853)
75. Yigang, X. U., & Yijing, L. I. (2007). Construction of recombinant Lactobacillus casei efficiently surface displayed and secreted porcine parvovirus VP2 protein and comparison of the immune responses induced by oral immunization. Immunology, 124, 68-75. (Pubitemid 351537574)
76. Cooper, J. A. (1993). Merozoite surface antigen-1 of Plasmodium. Parasitol Today, 9, 50-54.
77. Chandy, C. J., O'Donnell, R. A., Sumba, P. O., Moormann, A. M., de Koning-Ward, T. F., King, C. L., et al. (2004). Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-119) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa. Journal of Immunology, 173, 666-672. (Pubitemid 38797397)
78. Tian, J. H., Kumar, S., Kaslow, D. C., & Miller, L. H. (1997). Comparison of protection induced by immunization with recombinant proteins from different regions of merozoite surface protein 1 of Plasmodium yoelii. Infection and Immunity, 65, 3032-3036. (Pubitemid 27342374)
79. Zhang, Z.-H., Jiang, P.-H., Li, N.-J., Shi, M., & Huang, W. (2005). Oral vaccination of mice against rodent malaria with recombinant Lactococcus lactis expressing MSP119. World Journal of Gastroenterology, 11, 6975-6980. (Pubitemid 43126056)
80. Lujan, H. D., Mowatt, M. R., Conrad, J. T., Bowers, B., & Nash, T. E. (1995). Identification of a novel Giardia lamblia cyst wall protein with leucin-rich repeats. Implications for secretory granule formation and protein assembly into the cyst wall. Journal of Biological Chemistry, 270, 29307-29313.
81. Lee, P., & Faubert, G. M. (2006). Expression of the Giardia lamblia cyst wall protein 2 in Lactococcus lactis. Microbiology, 152, 1981-1990. (Pubitemid 44070455)
82. Kutzler, M. A., & Weiner, D. B. (2008). DNA vaccines: Ready for prime time. Nature Reviews, 9, 776-788.
83. Hu, Y.-C. (2005). Baculovirus as a highly efficient expression vector in insect and mammalian cells. Acta Pharmaceutica Sinica, 4, 405-416. (Pubitemid 40477987)
84. Fyan, E. F., Webster, R. G., Fuller, D. H., Haynes, J. R., Santoro, J. C., & Robinson, H. L. (1993). DNA vaccines: Protective immunization by parental, mucosal and gene gun inoculation. Proceedings of the National Academy of Science, 90, 11478-11482.
85. Jones, D. H., Clegg, J. C. S., & Farra, G. H. (1998). Oral delivery of micro-encapsulated DNA vaccines. In F. Brown & L. R. Haaheim (Eds.), Modulation of the immune response to vaccine antigens, vol 92: Development in biologics (pp. 149-155). Basel, Switzerland: Karger.
86. Steidler, L., Neiryunk, S., Huyghebaert, N., Snoeck, V., Vermiere, A., Godderis, B., et al. (2003). Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nature Biotechnology, 21, 785-789. (Pubitemid 36791397)
87. Braat, H., Rottiers, P., Hommes, D. W., Huyghebaert, N., Remaut, E., Remon, J. P., et al. (2006). A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clinical Gastroenterology and Hepatology, 4, 754-759. (Pubitemid 43841860)